-
North Korean women footballers arrive in South Korea: AFP
-
Rousey demolishes Carano in MMA comeback fight
-
German 'chemical town' fears impact of industrial decline
-
Qantas flight diverted after man bites flight attendant
-
India scrambles to steady rupee as oil shock bites
-
McGregor to make UFC return with Holloway rematch
-
WHO declares international emergency as Ebola outbreak kills more than 80 in DR Congo
-
Crackdown in Southeast Asia pushes scam networks to Sri Lanka
-
'Geek' hangout to tourist draw: Japan's maid cafes
-
Spacecraft to probe how Earth fends off raging solar winds
-
Bulgaria's 'Bangaranga' wins Eurovision, with Israel second
-
Musk wants SpaceX to go public. Here's how it works
-
Big risks and rewards in upcoming IPOs at SpaceX, OpenAI, Anthropic
-
Pal in last duo could ease nerves for PGA leader Smalley
-
Ronaldo suffers more agony as Al Nassr lose 1-0 in AFC final
-
Venezuela expels Maduro ally Alex Saab to US again
-
Rising star Woad in charge at LPGA Queen City Championship
-
Rodgers returning with Steelers for 22nd season
-
Rahm on PGA: 'It's a battle out there'
-
Dara: dancing to victory at Eurovision
-
As U.S. Markets Continue Surging to Historic All-Time Highs, ELEKTROS Believes This Could Be a Defining Opportunity for Penny Stock Investors Seeking Exposure to the Future of Lithium Mining, EV Infrastructure, and Next-Generation Electrification Technologies
-
Napoleon Solo wins 151st Preakness Stakes
-
Last 10 Eurovision winners
-
Smalley grabs PGA lead as wild final day showdown looms
-
Canada cruise passenger 'presumptive positive' for hantavirus
-
Five share PGA lead logjam with wild final day in store
-
Decision time at full-throttle Eurovision final
-
McIlroy charges into the hunt for epic major comeback win
-
Iran confirms squad heading to Turkey for World Cup preparation
-
Bolivian police clash with protesters blocking roads
-
Eurovision final kicks off with Viennese grandeur
-
Svitolina sees off Gauff to win Italian Open, Sinner in men's title showdown
-
Alonso set for appointment as Chelsea manager: reports
-
Spanish star Javier Bardem says 'narrative changing' on Gaza
-
Gujarat miss out on top spot as Kolkata stay alive in IPL
-
Charging McIlroy grabs share of the PGA lead
-
Rwanda genocide suspect Kabuga dead: court
-
No beer for City stars despite FA Cup win, says Guardiola
-
Modi oversees semi-conductor deal on Dutch trip
-
Americans 'should demonstrate like the French,' says Woody Harrelson
-
Vienna abuzz for Eurovision final
-
McFarlane eyes 'massive' Spurs clash after FA Cup final defeat
-
Scuffles from Europe to NYC as Swatch sale descends into chaos
-
Bielle-Biarrey helps Bordeaux-Begles avoid Top 14 slip-up before Champions Cup final
-
Man City still dream of Premier League glory after FA Cup win: Silva
-
Hearts broken as O'Neill summons Celtic's champion spirit
-
'Dance all night': Harry Styles kicks off World Tour in Amsterdam
-
Kane hits hat-trick, St. Pauli relegated from Bundesliga
-
Semenyo's magic moment fires Man City to FA Cup final win over Chelsea
-
Football back on war-battered pitches in Sudan capital
US panel recommends Covid vaccines for youngest children
A panel of experts convened by the US Food and Drug Administration unanimously recommended Covid-19 vaccines Wednesday for children under five, the final age group awaiting immunization in most countries.
Formal authorizations should follow soon, with the first shots in arms expected early next week, just over a year-and-a-half after the first Covid vaccines were greenlighted for the elderly in December 2020.
"This recommendation does fill a significant unmet need for a really ignored younger population," said Michael Nelson, a professor of medicine at the University of Virginia, one of the 21 experts asked to vote for the milestone meeting.
Unlike regulators in other countries, FDA offers livestreams of its internal deliberations and its stamp of approval is considered the global gold standard.
Opening the discussion, senior FDA scientist Peter Marks said that despite studies showing the majority of children have now been infected with the coronavirus, the high rate of hospitalizations among infants, toddlers and young children during last winter's Omicron wave underscored an urgent need for vaccination.
"We are dealing with an issue where we have to be careful we don't become numb to the pediatric deaths because of the overwhelming number of older deaths," he said.
"Every life is important and vaccine-preventable deaths are something we would like to try to do something about."
The United States has recorded 480 Covid deaths in the 0-4 age group in the pandemic -- far higher than even a bad flu season, Marks said.
As of May 2022, there have been 45,000 hospitalizations in that group, nearly a quarter of which required intensive care.
Ahead of the meeting, the FDA posted its independent analyses of the pharmaceutical companies' vaccines, deeming both safe and effective.
Both vaccines are based on messenger RNA, which delivers genetic code for the coronavirus spike protein to human cells that then grow it on their surface, training the immune system to be ready. The technology is now considered the leading Covid vaccination platform.
Pfizer sought authorization for three doses at three micrograms given to children aged six months through four years, while Moderna asked for the FDA to authorize its vaccine as two doses of a higher 25 micrograms for ages six months through five years.
Both vaccines were tested in trials of thousands of children. They were found to cause similar levels of mild side effects as in older age groups and triggered similar levels of antibodies.
- Two doses, or three? -
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent, compared to Moderna's estimates of 51 percent for children aged six-months to two years old and 37 percent for those aged two to five years.
But the Pfizer figure is based on very few cases and is thus considered preliminary. It also takes three doses to achieve its protection, with the third shot given eight weeks after the second, which is given three weeks after the first.
Moderna's vaccine should provide strong protection against severe disease after two doses, given four weeks apart, and the company is studying adding a booster that would raise efficacy levels against mild disease.
However, Moderna's decision to go with a higher dose is associated with higher levels of fevers in reaction to the vaccine compared to Pfizer.
There are some 20 million US children aged four years and under.
Although obesity, neurological disorders and asthma are associated with increased risk of severe disease among young children, it's not easy to predict severe outcomes.
In fact, 64 percent of hospitalizations in those under five occurred in patients without comorbidities.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition. Some three to six percent can experience long Covid symptoms for more than 12 weeks.
The FDA is expected to soon act on the panel's recommendation, and the matter will go to the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of 10 million shots at pharmacies and doctors' offices could begin as soon as June 21.
J.Williams--AMWN